Norditropin Nordilet 6.7 mg/mL (10 mg/1.5 mL) Solution For SC Injection Philippines - English - FDA (Food And Drug Administration)

norditropin nordilet 6.7 mg/ml (10 mg/1.5 ml) solution for sc injection

novo nordisk pharmaceuticals (philippines), inc.; distributor: novo nordisk pharmaceuticals (philippines), inc. - somatropin - solution for sc injection - 6.7 mg/ml (10 mg/1.5 ml)

Norditropin SimpleXx 5 mg / 1.5 mL Solution For Injection (SC) Philippines - English - FDA (Food And Drug Administration)

norditropin simplexx 5 mg / 1.5 ml solution for injection (sc)

n/a; importer: novo nordisk (pharmaceuticals) philippines, inc.; distributor: novo nordisk (pharmaceuticals) philippines, inc. - somatropin - solution for injection (sc) - 5 mg / 1.5 ml

Norditropin NordiLet New Zealand - English - Medsafe (Medicines Safety Authority)

norditropin nordilet

novo nordisk pharmaceuticals ltd - somatropin 6.66 mg/ml - solution for injection - 10 mg/1.5ml - active: somatropin 6.66 mg/ml excipient: histidine hydrochloric acid mannitol phenol poloxamer 188 sodium hydroxide water - treatment of growth failure in children due to chronic renal insufficency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as a glomerular filtration rate of for the treatment of severe growth failure due to intrauterine growth retardation (i.e. children born small for gestational age [sga] (birth weight and/or length <-2 sd) without spontaneous catch-up growth by 2 years of age). treatment of growth failure in children due to pituitary growth hormone deficiency treatment of growth failure in girls due to gonadal dysgenesis (turner's syndrome). treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml.latest regulatory activityapplication dateapplication typechange(s)statuspayment datepriority9/11/2016changed medicine notificationbulk active methods of manufacture; administrative fee (cmn); finished product manufacturing process - grade 3; test methods and specifications - grade 5; test methods and specifications - grade 6; shelf life/storage conditions - finished product; labelling - grade 1granted 20/2/201728/11/2016 27/11/2012new higher-risk medicine applicationadditional name - grade 2granted 19/12/201317/12/2012